Active immunization to tumor necrosis factor-α is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis by Delavallée, Laure et al.
Open Access
Available online http://arthritis-research.com/content/11/6/R195
Page 1 of 10
(page number not for citation purposes)
Vol 11 No 6 Research article
Active immunization to tumor necrosis factor-α is effective in 
treating chronic established inflammatory disease: a long-term 
study in a transgenic model of arthritis
Laure Delavallée1, Luca Semerano1,2, Eric Assier1, Géraldine Vogel3, Grégoire Vuagniaux4, 
Marion Laborie3, Daniel Zagury3, Natacha Bessis1 and Marie-Christophe Boissier1,2
1EA4222, Li2P, University of Paris 13, 74 rue Marcel Cachin, 93000, Bobigny, France
2Rheumatology Department, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), 125 rue de Stalingrad, 93000, Bobigny, France
3Neovacs SA, 3-4 impasse Reille, 75014, Paris, France
4Debiopharm SA, Chemin Messidor 5-7, Case Postale 5911, CH-1002, Lausanne, Switzerland
Corresponding author: Marie-Christophe Boissier, boissier@univ-paris13.fr
Received: 20 Oct 2009 Revisions requested: 2 Dec 2009 Revisions received: 11 Dec 2009 Accepted: 23 Dec 2009 Published: 23 Dec 2009
Arthritis Research & Therapy 2009, 11:R195 (doi:10.1186/ar2897)
This article is online at: http://arthritis-research.com/content/11/6/R195
© 2009 Delavallée et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Passive blockade of tumor necrosis factor-alpha
(TNF-α) has demonstrated high therapeutic efficiency in chronic
inflammatory diseases, such as rheumatoid arthritis, although
some concerns remain such as occurrence of resistance and
high cost. These limitations prompted investigations of an
alternative strategy to target TNF-α. This study sought to
demonstrate a long-lasting therapeutic effect on established
arthritis of an active immunotherapy to human (h) TNF-α and to
evaluate the long-term consequences of an endogenous anti-
TNF-α response.
Methods hTNF-α transgenic mice, which spontaneously
develop arthritides from 8 weeks of age, were immunized with a
heterocomplex (TNF kinoid, or TNF-K) composed of hTNF-α and
keyhole limpet hemocyanin after disease onset. We evaluated
arthritides by clinical and histological assessment, and titers of
neutralizing anti-hTNF-α antibody by enzyme-linked
immunosorbent assay and L929 assay.
Results Arthritides were dramatically improved compared to
control mice at week 27. TNF-K-treated mice exhibited high
levels of neutralizing anti-hTNF-α antibodies. Between weeks 27
and 45, all immunized mice exhibited symptoms of clinical
deterioration and a parallel decrease in anti-hTNF-α neutralizing
antibodies. A maintenance dose of TNF-K reversed the clinical
deterioration and increased the anti-hTNF-α antibody titer. At 45
weeks, TNF-K long-term efficacy was confirmed by low clinical
and mild histological scores for the TNF-K-treated mice.
Injections of unmodified hTNF-α did not induce a recall
response to hTNF-α in TNF-K immunized mice.
Conclusions Anti-TNF-α immunotherapy with TNF-K has a
sustained but reversible therapeutic efficacy in an established
disease model, supporting the potential suitability of this
approach in treating human disease.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease
with an estimated prevalence of about 0.5% in the adult pop-
ulation. This disease, characterized by synovial membrane
hyperplasia and immune cell infiltration, affects multiple
peripheral joints and leads to destruction of bone and carti-
lage, inducing pain and disability. Although its precise etiology
is still unknown, the pro-inflammatory cytokines, such as tumor
necrosis factor-alpha (TNF-α), interleukin (IL)-1β, IL-17, and
more recently IL-23, have been shown to be critical mediators
in the inflammatory process [1]. It has also been demonstrated
that TNF-α mediates a wide variety of effector functions in RA,
including the release of pro-inflammatory cytokines and chem-
okines, leukocyte accumulation, angiogenesis, and the
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activation of endothelial cells, chondrocytes, and osteoclasts
[2,3]. Based on the pivotal role of TNF-α in the pathogenesis
of RA [4], two classes of biologic drugs to block this cytokine
have been developed: a soluble TNF-α receptor (etanercept)
and TNF-binding monoclonal antibodies (mAbs) such as inflix-
imab, adalimumab, golimumab, or certolizumab [5,6]. Although
they show a rapid and substantial therapeutic benefit in most
patients, with a good safety profile, primary unresponsiveness
and secondary escape phenomena are not uncommon [7].
Nonetheless, the tremendous success of TNF-α blockade by
mAbs has sparked interest in developing alternative strategies
for antagonizing TNF-α, such as gene therapy by electrotrans-
fer [8], short interfering RNA [9], or active anti-TNF-α immuno-
therapy [10-13].
Active immunotherapy is based on the established principles
of vaccination. The aim of such a strategy is to use immuniza-
tion with a protein compound to generate high titers of neutral-
izing antibodies to a given antigen, which can be either a self-
protein or an environmental non-infectious agent. Therapeutic
immunization has produced promising results in several fields,
and in the case of active immunotherapy against cytokines
(AIC), the choice of the target cytokine is informed by the long-
term experience with mAbs, receptors, or antagonists in
inflammatory and autoimmune diseases [2]. Over the last dec-
ade, several active anti-TNF-α immunotherapies using mTNF-
α derivates as the immunogen have been developed and
tested in murine experimental models of RA [10,11,13].
More recently, with the aim of addressing diseases mediated
by human TNF-α (hTNF-α), we developed an anti-hTNF-α
compound called TNF kinoid (TNF-K), which is composed of
biologically inactive but immunogenic hTNF-α conjugated to a
carrier, keyhole limpet hemocyanin (KLH). We have tested
TNF-K in hTNF-α transgenic (TTg) mice, which overexpress
hTNF-α and develop an erosive polyarthritis that shares many
features with RA [14,15]. This model is the only relevant model
since anti-TNF antibodies generated by TNF-K target hTNF-α.
Previously, we have shown that a prophylactic anti-hTNF-α
immunization protected TTg mice OK from developing arthritis
[12,16]. To determine the potency of this compound against
established arthritis, we immunized TTg mice after the onset of
arthritis. We studied the animals for a long time period to eval-
uate the duration of the potential disease-modulating activity of
TNF-K. We showed that TNF-K immunization is efficacious
against established arthritis and induces a transient TNF
blockade with reversible effects on arthritis in TTg mice.
Materials and methods
Animals
Six- to nine-week-old male hemizygous TTg mice (1006-T)
were purchased from Taconic Farms (Germantown, NY, USA)
[14]. These mice are similar to Tg197 mice and develop a
spontaneous arthritis at from 8 to 10 weeks of age [15]. All
procedures were approved by the Animal Care and Use Com-
mittee of the University of Paris 13.
Reagents
We obtained hTNF-α kinoid (TNF-K), a protein complex of
hTNF-α and KLH, as previously described [16]. Dulbecco's
phosphate-buffered saline (PBS) was purchased from Eurobio
(Les Ulis, France). ISA-51 adjuvant was obtained from Seppic
(Paris, France).
Therapeutic and long-term effect of TNF-K active 
immunization
All treatments were started after the onset of arthritis, when
TTg mice reached an average clinical score of 3 out of 12. The
experimental protocol was as follows (Additional file 1). The
control group consisted of eight mice treated with PBS emul-
sified in ISA-51 adjuvant (PBS group) at 15, 16, and 19 weeks
of age. This group was followed for 12 weeks and then eutha-
nized for ethical reasons. A group of 23 TTg mice received
three primary intramuscular (IM) injections of TNF-K (4 μg)
emulsified in ISA-51 (TNF-K group) at 15, 16, and 19 weeks
of age. They were then randomly subdivided into two sub-
groups of eight and one subgroup of seven TTg mice. The first
eight mice were euthanized at 27 weeks of age to compare the
TNF-K immunized group with controls. At 32 weeks of age, the
subgroup of seven mice received a maintenance dose of TNF-
K emulsified in ISA-51 adjuvant, whereas the second sub-
group of eight mice received, as a control, an injection of PBS
emulsified in ISA-51 at the same time; both were followed until
45 weeks of age. In parallel, another group of eight mice was
given weekly intraperitoneal (IP) injections of infliximab (1 mg/
kg) from week 15 to week 27. At this time, infliximab was
discontinued.
Antibody assay
From blood samples collected at different time points during
the experiment and at sacrifice, sera were obtained and tested
for anti-KLH and anti-TNF-α antibody titers and for anti-TNF-α
antibody neutralizing capacity. Specific anti-hTNF-α and anti-
KLH antibody titers were determined using direct enzyme-
linked immunosorbent assay (ELISA) [12]. Precoated ELISA
plates with 100 ng per well hTNF-α or KLH were incubated
with serial dilutions of sera from immunized and control mice.
Specific IgGs were detected by using horseradish peroxi-
dase-conjugated rabbit anti-mouse IgG (Zymed Laboratories
Inc., now part of Invitrogen Corporation, Carlsbad, CA, USA).
The optical density (OD) was measured at 490 nm for each
well.
The neutralizing capacity was assessed by using the L929
cytotoxicity assay, reflecting neutralizing antibodies [12].
Briefly, mouse fibroblast L929 cell line (CCL 1) (American
Type Culture Collection, Manassas, VA, USA) was cultured in
Dulbecco's modified Eagle's medium containing 10% fetal
calf serum. The cells were seeded in flat-bottomed 96-wellAvailable online http://arthritis-research.com/content/11/6/R195
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plates and grown to 95% confluence. After 21 hours of incu-
bation at 37°C, serial dilution of serum with a 100% toxic
hTNF-α dose was added on L929 cells with 1 μg/mL of actin-
omycin D. After 20 hours of incubation at 37°C, the medium
was removed and replaced with MTS/PMS during 4 hours at
37°C. The OD at 490 nm was measured for each well. The
neutralization titer was expressed as the reciprocal of the
serum dilution that neutralizes 50% of hTNFα activity.
Evaluation of B-memory response after TNF-K 
immunization
Thirty-six TTg mice received three IM injections of TNF-K emul-
sified in ISA-51 adjuvant at 7, 8, and 11 weeks of age. They
were then randomly subdivided in two subgroups of ten and
two subgroups of eight TTg mice. Neutralizing anti-hTNF-α
antibody titers were monitored every month. When a decrease
of 50% of the neutralizing capacity of these antibodies was
observed, mice were intraperitoneally injected with native
hTNF-α (10 ng), native hTNF-α (100 ng), KLH (10 μg), or PBS
(equivalent volume) 24 weeks after the primary injection. Four
weeks later, these mice received IM injections of the same
compound with the same doses. The mice were further fol-
lowed for 10 weeks. The native hTNF-α doses were chosen
based on previous results we obtained in a TNF-α-dependent
lethal shock experiment, in which we showed that 1 μg of
native hTNF-α injections in TTg mice sensibilized with D-galac-
tosamine was enough to kill the mice [12].
Clinical and histological assessments
Blinded weekly monitoring of body weight and arthritis scores
in all four limbs was started from the reception of the animals
(9 weeks of age). Clinical severity of arthritis for each paw (fin-
gers, tarsus, and ankle) was quantified by attributing a score
ranging from 0 to 3: 0, normal; 1, slight redness and swelling;
2, pronounced edematous swelling of the entire foot; 3, joint
deformity and rigidity [12]. The scores of each paw were
summed, resulting in an arthritis score ranging from 0 to 12.
The mean arthritis score on each clinical observation day was
calculated for each treatment group.
For histological assessment of arthritis, all animals were sacri-
ficed after 18-week or 36-week follow-up. Left forelimbs and
right hind paws were collected, fixed with formol, decalcified,
dehydrated, and included in paraffin blocks. Slides of 5 μm in
thickness were made using a microtome. At least four serial
sections were realized for each paw in order to obtain a relia-
ble spatial evaluation of articular hints. Slides were then
stained with hematoxylin and eosin or with safranin-O before
microscopic observation (optical microscope). Synovitis and
bone erosions were defined on slides stained with hematoxylin
and eosin. Lesions were evaluated quantitatively on each slide
using a 3-point scale ranging from 0 to 3, where 0 = normal
articulation; 1 = slight inflammation and thickening of the syn-
ovium; 2 = mild thickening of the synovium and mild inflamma-
tion with invasion of the subsynovial area by inflammatory cells;
3 = severe inflammation and massive invasion of adjacent tis-
sues by pannus [17]. Other sections were scored for loss of
safranin-O staining as a measure of cartilage proteoglycan
depletion using a scale from 0 to 3, where 0 = no depletion; 1
= depletion of staining and thinning down of the lateral super-
ficial layer; 2 = depletion of staining and thinning down of the
central superficial layer; 3 = severe and mostly complete
depletion of staining in the superficial layer [18].
Statistical analysis
Data distribution was preliminarily checked by the Kol-
mogorov-Smirnov test. Serial measurements of clinical scores,
body weight, antibody titers, and antibody neutralizing capac-
ity were analyzed considering the area under the curve for
each subject as a summary measure; these measures were
then analyzed as raw data [19]. According to data distribution
and number of groups, a parametric (analysis of variance
[ANOVA],  t  test) or non-parametric (Kruskal-Wallis, Mann-
Whitney) test was then performed. Post hoc comparisons
were performed with the appropriate test according to data
distribution (Student-Newman-Keuls for parametric data and
Dunn test for non-parametric data). Clinical score time trend
was analyzed by Spearman rho, and 95% confidence intervals
(CIs) were given. Histological scores were compared with
ANOVA or Kruskal-Wallis and their appropriate post hoc anal-
ysis according to data distribution. Differences in antibody titer
at different time points were analyzed with repeated measures
ANOVA due to normal distribution of data. Incidences of arthri-
tis were compared using Fisher exact test with Yates correc-
tion. All statistics were performed with MedCalc statistical
software version 10.4.8 (MedCalc Software bvba, Mariakerke,
Belgium).
Results
Effect of TNF-K immunization in TTg mice on established 
arthritis
We investigated the potency of anti-hTNF-α immunization
against established arthritis. To address this question, TTg
mice, which develop spontaneous arthritis at around 8 to 10
weeks of age, were monitored for any signs of clinical arthritis
from 9 weeks of age. When the mice exhibited an average clin-
ical score of 3 (scoring range from 0 to 12; see Materials and
methods), treatments were started for all of the mice. The con-
trol group (eight mice) was injected with PBS emulsified with
ISA-51 adjuvant (PBS group) at 15, 16, and 19 weeks of age
and developed severe arthritis over a 12-week period. At 27
weeks of age, these mice were euthanized for ethical reasons
(Figure 1a). Compared with the control group, TNF-K immu-
nized mice, receiving injections following the same time
schedule, showed a dramatic improvement of the disease after
immunization (P  < 0.05 versus control group) (Figure 1a),
demonstrating good efficacy of the TNF-K treatment against
established arthritis. TNF-K immunized mice exhibited lower
peak clinical scores and fewer inflamed paws than control ani-
mals (data not shown). The infliximab-treated group showed,Arthritis Research & Therapy    Vol 11 No 6    Delavallée et al.
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as expected, a significant improvement of the disease (Figure
1a), with lower scores than the PBS group (P < 0.05 at week
27). Based on a comparison of clinical scores, the TNF-K
immunized and infliximab-treated mice showed comparable
efficacy, with no statistically significant differences, although
the infliximab has a more rapid efficacy than TNF-K immuniza-
tion. We did not observe significant differences in body weight
in any studied group (Figure 1b).
We next investigated the histological efficacy of TNF-K vac-
cine. At 27 weeks of age, eight TNF-K immunized mice and all
control animals were euthanized. We observed that the clinical
assessment was corroborated by histological evaluation
(Table 1). All control mice exhibited significant histological
signs of arthritis, whereas all TNF-K immunized mice showed
lower inflammation scores compared with the control group
(Table 1 and Figure 2a, b). In regard to joint destruction, TNF-
K immunized TTg mice did not exhibit any signs of cartilage
damage while the control group showed extensive cartilage
destruction (P < 0.05) (Table 1). We did not evaluate the his-
tological efficacy of infliximab on TTg mice at 27 weeks of age.
For histological arthritis, we observed specific diffusion and
pale proteoglycan coloration by safranin-O, reflecting cartilage
degradation for control PBS mice in comparison with TNF-K-
treated animals (Figure 2c, d).
Reversibility of TNF-α blockade
As TNF-K treatment is able to improve established arthritis
based on 12-week follow-up, we investigated the duration of
its disease-modulating activity over a longer period. To explore
this, we extended by 18 weeks the study of the TNF-K immu-
nized TTg mice for a total study duration of 30 weeks after the
first immunization. We observed that, at around 23 weeks of
age, arthritis clinical scores started to increase slightly with
time (Figure 1a). A time-trend analysis of the clinical scores of
both groups having received the primary course of three injec-
tions of TNF-K from 21 to 32 weeks of age shows a positive
correlation of clinical scores with the age of mice (ρ = 0.194,
95% CI 0.043 to 0.337, P < 0.05), demonstrating the transi-
tory effect of anti-hTNF-α immunization (Figure 3a). Further-
more, we observed that, over this period, the number of
inflamed paws of TNF-K immunized mice increased compared
with that of TNF-K immunized animals sacrificed at 27 weeks
of age (P < 0.05, data not shown). Histological comparisons
were then made between groups of TNF-K immunized mice
sacrificed at week 27 and those at week 45. This showed a
mild progression of the disease over this 18-week period, with
higher inflammation and destruction scores for all of the ani-
mals in the week 45 groups (Table 1).
Effect of a maintenance dose
We next investigated whether this flare in arthritis disease
could be ameliorated by the administration of a maintenance
dose (late boost) of TNF-K. Therefore, seven TTg mice that
had received a primary course of three injections of TNF-K
were administered a maintenance dose of TNF-K at 32 weeks
of age. As a control, the remaining eight TTg mice that had
received the primary course were injected with PBS emulsified
in ISA-51 adjuvant. The arthritis clinical score curves
decreased for mice that received the maintenance dose and
increased for the controls (Figure 1a). The differential in clini-
cal scores between the two groups did not reach statistical
significance, and this was due to the small sample size related
to effect size. (With an alpha error of 0.05 and a beta error of
0.2, a sample size of 22 mice would have been necessary for
the detected difference to be statistically significant.) Never-
Figure 1
Clinical evaluation of human tumor necrosis factor-alpha transgenic  (TTg) mice immunized with tumor necrosis factor kinoid (TNF-K) or  phosphate-buffered saline (PBS) or treated with infliximab (IFX) Clinical evaluation of human tumor necrosis factor-alpha transgenic 
(TTg) mice immunized with tumor necrosis factor kinoid (TNF-K) or 
phosphate-buffered saline (PBS) or treated with infliximab (IFX). TTg 
mice were immunized with TNF-K or PBS emulsified in ISA-51 adjuvant 
or were IFX-treated. All mice were monitored for clinical signs of arthri-
tis and for weight for 18 or 36 weeks. (a) TTg mice received three pri-
mary injections at 15, 16 and 19 weeks of age (open arrows) of TNF-K 
(n = 15, open and closed diamonds) or PBS (n = 8, squares). At 32 
weeks of age (shaded arrow), TTg mice received a maintenance dose 
(md) of TNF-K (n = 7, open diamonds) or an injection of PBS emulsified 
in ISA-51 adjuvant (n = 8, closed diamonds). Eight TTg mice (circles) 
received weekly intraperitoneal injections of IFX (bold arrows) from 
week 15 for a period of 12 weeks (until 27 weeks of age). (b) The 
weight gain of all groups is represented. Results are expressed as 
mean ± standard error of the mean. *P < 0.05 versus PBS.Available online http://arthritis-research.com/content/11/6/R195
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theless, clinical score time-trend analysis with Spearman rho
showed a reduction of the scores for maintenance-dosed mice
(ρ = -0.249, 95% CI -0.448 to -0.026, P < 0.05) and a dete-
rioration for controls (ρ = 0.405, 95% CI 0.214 to 0.567, P <
0.05), supporting the efficacy of a maintenance dose of TNF-
K in treating the late flare of arthritis (Figure 3b, c).
Histological inflammation and destruction were assessed at
45 weeks of age (Table 1). All of the immunized animals exhib-
ited mild signs of histological inflammation and destruction of
ankle and knee joints. As with the clinical scores, the differ-
ences between immunized animals that received the mainte-
nance dose and those that did not were not statistically
significant (Table 1).
We also compared the clinical efficacy of TNF-K active immu-
nization with infliximab intermittent treatment on arthritis of TTg
mice over this 18-week extension period. No statistically sig-
nificant difference was detected between the two treatments
(Figure 1a). However, as would be expected, the clinical
scores of the infliximab group deteriorated over time since
treatment was withdrawn at 27 weeks of age (Figure 3d).
Figure 2
Examples of histological evaluation of tumor necrosis factor-alpha transgenic (TTg) mice immunized with tumor necrosis factor kinoid (TNF-K) or  phosphate-buffered saline (PBS) Examples of histological evaluation of tumor necrosis factor-alpha transgenic (TTg) mice immunized with tumor necrosis factor kinoid (TNF-K) or 
phosphate-buffered saline (PBS). Histological sections (magnification × 40) of the knees of TNF-K- or PBS-treated mice were prepared (see Mate-
rials and methods) and colored with hematoxylin and eosin (a, b) to observe synovial inflammation or with safranin-O (c, d) to observe cartilage deg-
radation. For the histological sections of TTg mice immunized with TNF-K, inflammation (a) and destruction (c) were scored at 0; for the control 
group, inflammation (b) and destruction (d) were scored at 2. Black arrows show thickness and inflammatory infiltration of synovial membrane in (b) 
and a normal appearance in (a). White arrows show depletion of proteoglycan (a marker for cartilage destruction) in (d) and a normal full-red staining 
in (c).Arthritis Research & Therapy    Vol 11 No 6    Delavallée et al.
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We further examined the histology of infliximab intermittent-
treated TTg mice sacrificed at 45 weeks of age. All of the mice
from this group, treated with infliximab during 12 weeks, had
developed severe inflammation and exhibited mild cartilage
destruction of the joints 18 weeks after the infliximab with-
drawal (Table 1 and Additional file 1). By comparison, TNF-K
immunized animals, receiving or not receiving the maintenance
dose, showed lesser inflammation and cartilage destruction
compared with the infliximab group (P < 0.05) (Table 1).
Anti-TNFα antibodies after TNF-K immunization
To evaluate the duration of the immune response after immu-
nization with TNF-K in TTg mice, we assessed the titers and
the neutralizing capacity of anti-hTNF-α antibodies in sera of
Table 1
Histological evaluation of arthritis in human tumor necrosis factor (TNF)-alpha transgenic mice immunized with TNF kinoid
Group Number of mice Inflammation score Incidence Destruction score Incidence
TNF-K (3 injections, sacrifice at week 27) 8 0.1 ± 0.1a 2/8b 0.0 ± 0.0a 1/8c
TNF-K (3 injections without maintenance dose, sacrifice 
at week 45)
80 . 6  ±  0 . 2 d 6/8 0.2 ± 0.1d 3/8
TNF-K (3 injections with maintenance dose, sacrifice at 
week 45)
70 . 5  ±  0 . 1 d 7/7 0.3 ± 0.1d 5/7
Intermittent infliximab (sacrifice at week 45) 8 1.4 ± 0.1 8/8 0.9 ± 0.2 7/8
Phosphate-buffered saline (sacrifice at week 27) 8 1.6 ± 0.1 8/8 0.9 ± 0.2 7/8
The incidence of inflammation/destruction as evaluated by histology is the number of mice with a score of inflammation/destruction of at least 
0.25. Results are given as mean ± standard error of the mean. aP < 0.05 versus phosphate-buffered saline (PBS); bP < 0.01 versus PBS; cP < 
0.05 versus PBS; dP < 0.05 versus infliximab. TNF-K, tumor necrosis factor kinoid.
Figure 3
Clinical score time trend Clinical score time trend. The severity of disease evolution over time was analyzed using Spearman rank correlation. We correlated clinical scores 
with the age of the mice, expressed in weeks, and divided the study into two periods of time. (a) Correlation between week 21 and week 32 for all 
of the immunized mice (n = 15). We observed an aggravation of disease in all mice immunized with tumor necrosis factor kinoid (TNF-K) a couple of 
weeks after the last immunization. (b) Correlation between week 33 and week 45 for immunized mice not receiving the maintenance dose (md). We 
observed an aggravation of the severity of the disease. (c) Correlation between week 33 and week 45 for immunized mice receiving the mainte-
nance dose. After the maintenance dose at 32 weeks of age, we observed an amelioration of the scores. (d) Correlation between week 28 and week 
45 for infliximab-treated mice. The injections were stopped at week 27, and we observed an aggravation of the disease over time thereafter. CI, con-
fidence interval.
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Figure 4
Evaluation of anti-human tumor necrosis factor-alpha (anti-hTNF-α) anti- body production in TNF-α transgenic (TTg) mice immunized with TNF  kinoid (TNF-K) Evaluation of anti-human tumor necrosis factor-alpha (anti-hTNF-α) anti-
body production in TNF-α transgenic (TTg) mice immunized with TNF 
kinoid (TNF-K). TTg mice were immunized at 15, 16, and 19 weeks of 
age (open arrows) with TNF-K. (a) Enzyme-linked immunosorbent 
assay of anti-hTNF-α antibodies. (b) The neutralizing capacity of the 
anti-hTNF-α antibody was evaluated on L929 cells and is expressed as 
the mean of the reciprocal of the serum dilution that neutralizes 50% of 
hTNF-α activity (NC50). Closed histograms represent mice that did not 
receive the TNF-K maintenance dose (TNF-K without md) at 32 weeks 
of age (shaded arrow). Open histograms represent mice that did 
receive it (TNF-K with md). Results are expressed as mean ± standard 
error of the mean. *P < 0.05.
TNF-K immunized TTg mice and of the PBS group. High levels
of anti-hTNF-α antibodies were detected only in TNF-K immu-
nized mice (Figure 4a). These antibodies were neutralizing as
evaluated by L929 cytotoxic assay (Figure 4b). Mice receiving
the maintenance dose at week 32 exhibited a significant
increase in neutralizing anti-hTNF-α antibody titers as early as
3 weeks after the maintenance dose. Conversely, mice treated
with PBS at week 32 showed a slow decrease in their neutral-
izing anti-hTNF-α antibody titers (Figure 4). At sacrifice, the
neutralizing anti-hTNF-α antibody titers had decreased for
both groups (Figure 4).
B-memory response against TNF-α after TNF-K 
immunization
We wished to evaluate the response of the immune system to
native (that is, unmodified) hTNF-α after immunization with the
TNF-K. We immunized TTg mice with TNF-K; once we
observed a clear diminution of the neutralizing anti-hTNF-α
antibody titer (Additional file 2), we injected native hTNF-α into
the TNF-K immunized mice with a view to establishing whether
this native hTNF-α injection induced an anti-hTNF-α response
(Figure 5b, d). Control groups received injections of native
KLH or PBS (Figure 5e-h). We observed that injections of
native hTNF-α (10 or 100 ng) had no effect on titers of either
neutralizing anti-hTNF-α antibody (Figure 5b, d) or anti-KLH
antibody (Figure 5a, c). On the other hand, injections of KLH
induced a dramatic increase in anti-KLH antibody titer (Figure
5e), indicating a recall response to KLH. Moreover, injection of
KLH had no impact on the production of anti-hTNF-α neutral-
izing antibody (Figure 5f). PBS injections had no impact on the
production of either anti-KLH or neutralizing anti-hTNF-α anti-
bodies (Figure 5 g, h). Four weeks after injections by the IP
route, each group of mice received IM injections of the same
compound at the same dose. Anti-KLH antibody titers further
increased while neutralizing anti-hTNF-α antibody titers
remained stable over time (data not shown).
Discussion
In the present study, we show in a long-term follow-up that
TNF-K immunization dramatically improves the disease status
of clinically established arthritis. When the active immunization
was administered after the onset of active disease, its benefi-
cial effect, mediated by the production of a high titer of neutral-
izing anti-hTNF-α antibodies, was evident both in clinical
symptoms and in the histological indicators for arthritis. Addi-
tionally, in these experiments, we evaluated the effect of TNF-
α blockade over a long-term period and showed the long-last-
ing efficacy and the reversible effect of TNF-K immunization.
Moreover, we present evidence that no B-cell memory
response to native hTNF-α was induced by TNF-K
immunization.
Active immunization has previously shown its efficacy in sev-
eral experimental models of human autoimmune diseases, as
well as other pathologies, using cytokines cross-linked to
virus-like particles of the bacteriophage Qβ [13,20,21] or
complexed with KLH (kinoids) [16,22,23]. The numerous clin-
ical trials that have been performed or that are under way sup-
port both the feasibility and the safety of the use of active
immunization against self-proteins in humans [24-27].
Major questions with our active anti-cytokine immunotherapy
targeting TNF-α, a pleiotropic cytokine, are the depth and the
duration of the TNF-α inhibition [2]. In contrast with the previ-
ous studies, the present one has been performed with a long-
term clinical follow-up (over a 36-week period). Importantly,
our present data show a decrease in anti-hTNF-α neutralizingArthritis Research & Therapy    Vol 11 No 6    Delavallée et al.
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Figure 5
B-memory response after tumor necrosis factor kinoid (TNF-K) immunization B-memory response after tumor necrosis factor kinoid (TNF-K) immunization. Thirty-six human tumor necrosis factor-alpha (hTNF-α) transgenic mice 
were immunized with TNF-K at 7 (day 0), 8 (day 7), and 11 (day 28) weeks of age. Bleeding was done every month from 12 weeks of age (day 38) 
until sacrifice. When we observed a decline of the anti-hTNF-α neutralizing antibody titer (closed symbols), we injected intraperitoneally (arrow) 
native hTNF-α (10 ng, n = 10, diamonds) (a, b), native hTNF-α (100 ng, n = 9, squares) (c, d), keyhole limpet hemocyanin (KLH) (10 μg, n = 10, cir-
cles) (e, f), or phosphate-buffered saline (equivalent volume, n = 10, triangles) (g, h). We studied the anti-KLH antibody titer (open symbols) and 
neutralizing anti-hTNF-α antibody titer (closed symbols) for 10 weeks (70 days). Each single plot represents the antibody titer of one mouse. The 
bold line represents the mean antibody titer at each time point. *P < 0.001 versus day 149; **P < 0.0001 versus day 171; #P < 0.05 versus day 
178; ##P < 0.05 versus day 149. NC50, mean of the reciprocal of the serum dilution that neutralizes 50% of hTNF-α activity.
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antibodies after a peak 8 weeks after immunization. At the
same time, comparisons of histological scores of TNF-K-
treated animals at week 27 and week 45 showed a slight pro-
gression over time of arthritides. These data support the
hypotheses of both residual hTNF-α activity and the reversibil-
ity of the blockade of hTNF-α in vaccinated animals. Further-
more, a maintenance dose given 17 weeks after treatment
initiation both increased the anti-hTNF-α neutralizing antibod-
ies and ameliorated the course of disease, demonstrating that
the immune system remains responsive to TNF-K
immunization.
In the present study, we have also demonstrated the B-mem-
ory response to hTNF-α after TNF-K vaccination. When we
stimulated the immune system of TNF-K immunized transgenic
mice, we demonstrated that IP injection of KLH dramatically
induced the production of new anti-KLH antibodies. This B-
cell memory response to KLH was not accompanied by any
increase of anti-hTNF-α neutralizing antibody titers. Further-
more, injections of native autoantigen hTNF-α after active
immunization with TNF-K against hTNF-α did not induce the
production of new neutralizing anti-hTNF-α autoantibodies,
demonstrating no B-cell memory response to native hTNF-α.
These data suggest that in physiopathological situations in
which native hTNF-α production would be stimulated (for
example, infections), it would not be thwarted by an immuniza-
tion with TNF-K performed a long time before. Taken together,
these data are consistent with the transient production and
effect of neutralizing anti-hTNF-α antibodies after TNF-K
immunization.
Finally, we demonstrated that TNF-K and infliximab have com-
parable efficacy measured by clinical parameters in our model.
Moreover, once infliximab weekly injections were discontinued
(at 27 weeks of age), infliximab-treated mice exhibited a wors-
ening of arthritides over time following the withdrawal of inflix-
imab. Histopathological scores of these animals were
significantly higher than those of TNF-K immunized mice, with
or without late maintenance dose.
Conclusions
Our data show that active immunotherapy with TNF-K induced
a long-lasting improvement in an RA model. The occurrence of
a disease flare in previously immunized mice, the bell-shaped
neutralizing anti-hTNF-α antibody curve, the increase of anti-
hTNF-α neutralizing antibodies after a maintenance dose, and
the absence of evidence of in vivo B-cell memory response to
native hTNF-α are all elements supporting a favorable benefit-
risk ratio for such a strategy and a transient response against
hTNF-α after TNF-K immunization. Further studies should be
performed to evaluate the risk of infections or tumors under
TNF-K treatment in dedicated models since their occurrences
are a matter of debate in patients treated with passive immu-
notherapies against TNF-α [28,29].
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